第二代钆-铋超小纳米颗粒增强临床放疗效果并提供临床磁共振成像对比
该研究在两种非小细胞肺癌(NSCLC)模型中评估了将AGuIX中70%钆原子替换为铋原子的新一代AGuIX-Bi纳米颗粒在临床兆伏级放疗和磁共振成像(MRI)条件下的疗效。结果显示AGuIX-Bi联合放疗在抑制肿瘤生长方面显著优于生理盐水联合放疗和AGuIX联合放疗,同时维持了足够的3T MRI对比度。
要点
- AGuIX-Bi联合放疗较AGuIX联合放疗显著延长肿瘤倍增时间,A549模型增加160%,LLC模型增加60%。
- AGuIX-Bi的纵向弛豫率常数r1为8.4/mM/s,高于AGuIX的6.9/mM/s。
- AGuIX-Bi在3T MRI小鼠肿瘤成像中的对比噪声比约为AGuIX的一半。
核心结论
- AGuIX-Bi纳米颗粒在两种NSCLC模型中较AGuIX更有效地延迟肿瘤生长,同时在3T下维持足够的MRI对比度。
- 用铋原子替换部分钆原子可在临床兆伏级能量下提高AGuIX纳米颗粒的疗效而不损害成像。
研究设计与样本
- 研究在LLC鼠源和A549人源NSCLC小鼠模型中开展,动物接种后分为对照组(生理盐水、AGuIX、AGuIX-Bi)和照射组(生理盐水+RT、AGuIX+RT、AGuIX-Bi+RT)。
- 纳米颗粒在给予10 Gy照射(6 MV无均整滤过器束)前24小时注射,肿瘤测量至需要安乐死时,以肿瘤倍增时间作为终点。
- 使用3T临床MRI扫描仪对AGuIX和AGuIX-Bi体模进行T1加权成像和T1映射,并对A549接种小鼠在注射后2小时和24小时进行T1图像采集。
主要发现
- 未观察到因纳米颗粒注射、麻醉或照射导致的毒性。
- 在LLC和A549两种模型中,AGuIX-Bi+RT在减少肿瘤生长方面显著优于生理盐水+RT和AGuIX+RT(P < .05)。
- AGuIX-Bi+RT组较AGuIX+RT组的中位肿瘤倍增时间在A549模型中增加160%,在LLC模型中增加60%(P < .05)。
- 体模T1映射得出的纵向弛豫率常数r1为AGuIX 6.9/mM/s、AGuIX-Bi 8.4/mM/s。
- 小鼠肿瘤T1加权成像显示AGuIX-Bi的对比噪声比约为AGuIX的一半。
临床怎么用
- AGuIX-Bi可在临床兆伏级放疗条件下作为放射增敏剂,同时利用其MRI对比能力进行成像引导。
- 用铋替换部分钆的策略可在不牺牲3T MRI对比度的情况下增强放疗效果。
局限性
- 研究仅基于两种NSCLC小鼠模型,尚未在人体中验证。
- AGuIX-Bi的对比噪声比约为AGuIX的一半,成像对比度有所降低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: AGuIX nanoparticles consisting of Gd atoms chelated to a polysiloxane matrix are under clinical evaluation as radiopharmaceuticals agents with radiation therapy (RT). A new generation, AGuIX-Bi, replaces 70% of the Gd atoms in AGuIX with Bi atoms, improving radiation dose amplification while maintaining magnetic resonance imaging (MRI) contrast. The therapeutic efficacy of AGuIX-Bi was investigated under clinical megavoltage and MRI conditions in 2 non-small cell lung cancer (NSCLC) models. METHODS AND MATERIALS: Murine (LLC) and human (A549) NSCLC were studied in mice, with animals inoculated and divided into cohorts for control (saline, AGuIX, and AGuIX-Bi) and irradiation (saline + RT, AGuIX + RT, and AGuIX-Bi + RT). Nanoparticle cohorts were injected 24 hours before delivering 10 Gy of irradiation using a 6 MV flattening-filter-free beam. Tumors were measured until euthanasia was necessary, taken as time-to-tumor doubling. Additionally, AGuIX and AGuIX-Bi phantoms were constructed with T1-weighted images and maps taken using a 3T clinical MRI scanner. T1-images of A549 inoculated mice were obtained on the same scanner with injection of AGuIX or AGuIX-Bi 2- and 24 hours before imaging. RESULTS: No toxicity was observed because of nanoparticle injection, anesthesia, or irradiation. In both LLC and A549 models, AGuIX-Bi + RT significantly outperformed both saline + RT and AGuIX + RT in reducing tumor growth (P < .05). Median time-to-tumor doubling for AGuIX-Bi + RT compared with AGuIX + RT groups was increased by 160% for A549, and by 60% for LLC models (P < .05). Longitudinal relaxivity constants (r1) derived from phantom T1-mapping were 6.9/mM/s for AGuIX and 8.4/mM/s for AGuIX-Bi. Additionally, T1-weighted mouse tumor imaging showed contrast-to-noise of AGuIX-Bi to be roughly half that of AGuIX. CONCLUSIONS: AGuIX-Bi nanoparticles proved more effective than AGuIX at delaying tumor growth for both NSCLC models while maintaining sufficient MRI contrast at 3T. Replacing some Gd atoms with bismuth improves the efficacy of AGuIX nanoparticles under clinical megavoltage energies without compromising imaging.
引用
- Morris T, Muradova Z, Brown N, et al. Second-Generation Gadolinium-Bismuth Ultrasmall Nanoparticles Amplify the Effects of Clinical Radiation Therapy and Provide Clinical Magnetic Resonance Imaging Contrast. Int J Radiat Oncol Biol Phys. 2025. PMID: 40348199. doi:10.1016/j.ijrobp.2025.04.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。